• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

男性乳腺癌：重新审视我们的观点。

Male Breast Cancer: Reevaluate Our Opinion.

作者信息

Kale Santosh, Rammohan Rajmohan, Vas Vilma, Elsayad Chris

机构信息

Department of Internal Medicine, Nassau University Medical Center, East Meadow, Nassau County, NY, USA.

出版信息

Case Rep Oncol Med. 2020 Feb 6;2020:6245415. doi: 10.1155/2020/6245415. eCollection 2020.

DOI:10.1155/2020/6245415
PMID:32089923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7026701/
Abstract

Male breast cancers (MBCs) are relatively uncommon malignancy with less than 1% incidence. MBC presents at a later age with a more advanced presentation as compared to the female breast cancer. Due to the paucity of the number of cases and trials regarding the MBC, female breast cancer treatment protocols are applied. Mastectomy and hormonal therapy remains the mainstay of treatment. Moreover, the data about prognosis of MBC remains limited.

摘要

男性乳腺癌（MBC）是一种相对罕见的恶性肿瘤，发病率低于1%。与女性乳腺癌相比，MBC发病年龄较晚，临床表现更为晚期。由于关于MBC的病例和试验数量较少，因此采用女性乳腺癌的治疗方案。乳房切除术和激素治疗仍然是主要的治疗方法。此外，关于MBC预后的数据仍然有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/864e1a341da0/CRIONM2020-6245415.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/d4f6cf01dd60/CRIONM2020-6245415.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/d9fa07db5653/CRIONM2020-6245415.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/41b2aab4746d/CRIONM2020-6245415.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/4fa2811e1b49/CRIONM2020-6245415.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/a93839ad75e8/CRIONM2020-6245415.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/864e1a341da0/CRIONM2020-6245415.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/d4f6cf01dd60/CRIONM2020-6245415.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/d9fa07db5653/CRIONM2020-6245415.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/41b2aab4746d/CRIONM2020-6245415.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/4fa2811e1b49/CRIONM2020-6245415.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/a93839ad75e8/CRIONM2020-6245415.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7380/7026701/864e1a341da0/CRIONM2020-6245415.006.jpg

相似文献

1
Male Breast Cancer: Reevaluate Our Opinion.男性乳腺癌：重新审视我们的观点。
Case Rep Oncol Med. 2020 Feb 6;2020:6245415. doi: 10.1155/2020/6245415. eCollection 2020.
2
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.基因表达谱分析显示，髓样乳腺癌是基底样乳腺癌的一个亚组。
Cancer Res. 2006 May 1;66(9):4636-44. doi: 10.1158/0008-5472.CAN-06-0031.
3
Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.男性乳腺癌的长期生存及BRCA状态：一项回顾性单中心分析
BMC Cancer. 2016 Jul 4;16:375. doi: 10.1186/s12885-016-2414-y.
4
New approaches in the management of male breast cancer.男性乳腺癌的治疗新方法。
Clin Breast Cancer. 2013 Oct;13(5):309-14. doi: 10.1016/j.clbc.2013.04.003. Epub 2013 Jul 9.
5
Male breast cancer: a gender issue.男性乳腺癌：一个性别问题。
Nat Clin Pract Oncol. 2006 Aug;3(8):428-37. doi: 10.1038/ncponc0564.
6
Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review.男性乳腺癌：放射治疗对两例患者的局部控制效果良好及相关文献综述
Eur J Med Res. 2015 Nov 26;20:94. doi: 10.1186/s40001-015-0173-x.
7
Clinical Diagnosis and Treatment of Male Breast Cancer:Analysis of 24 Cases.男性乳腺癌的临床诊断与治疗：24例分析
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2017 Aug 20;39(4):568-572. doi: 10.3881/j.issn.1000-503X.2017.04.017.
8
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.男性乳腺癌的临床特征：20 多年来 7 家机构的经验。
Cancer Res Treat. 2016 Oct;48(4):1389-1398. doi: 10.4143/crt.2015.410. Epub 2016 Apr 11.
9
Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.男性乳腺癌：来自伊朗克尔曼沙阿省放射肿瘤学系的报告。
Asian Pac J Cancer Prev. 2016;17(5):2593-6.
10
Responding to the challenges of breast cancer in egypt and other arab countries.应对埃及及其他阿拉伯国家乳腺癌带来的挑战。
J Egypt Natl Canc Inst. 2008 Dec;20(4):309-12.

本文引用的文献

1
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
2
Male Breast Cancer.男性乳腺癌
J Breast Health. 2016 Jan 1;12(1):1-8. doi: 10.5152/tjbh.2015.2711. eCollection 2016 Jan.
3
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development.BRCA1和BRCA2基因突变在乳腺癌发生发展中的重要性。
Med J Islam Repub Iran. 2016 May 15;30:369. eCollection 2016.
4
Male breast cancer, clinical presentation, diagnosis and treatment: Twenty years of experience in our Breast Unit.男性乳腺癌：临床表现、诊断与治疗——我们乳腺科二十年的经验
Int J Surg Case Rep. 2016;20S(Suppl):8-11. doi: 10.1016/j.ijscr.2016.02.004. Epub 2016 Feb 26.
5
Breast Cancer: Epidemiology and Etiology.乳腺癌：流行病学与病因学
Cell Biochem Biophys. 2015 Jun;72(2):333-8. doi: 10.1007/s12013-014-0459-6.
6
HER2-positive male breast cancer: an update.HER2 阳性男性乳腺癌：最新进展。
Breast Cancer (Dove Med Press). 2010 Oct 4;2:45-58. doi: 10.2147/BCTT.S6519.
7
Men with breast cancer have same disease-specific and event-free survival as women.男性乳腺癌患者的疾病特异性生存率和无事件生存率与女性相同。
Ann Surg Oncol. 2009 Apr;16(4):972-8. doi: 10.1245/s10434-009-0327-6. Epub 2009 Jan 30.
8
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.他莫昔芬用于早期乳腺癌：随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 May 16;351(9114):1451-67.
9
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.采用激素、细胞毒性或免疫疗法对早期乳腺癌进行全身治疗。133项随机试验，涉及75000名女性中的31000例复发和24000例死亡。早期乳腺癌试验协作组。
Lancet. 1992 Jan 4;339(8784):1-15.